Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCAR017 vs Standard of Care in R/R Aggressive B-cell NHL
NCT03575351Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2018
- Primary completion
- Oct 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 12
01
Overview
A Phase 3 trial of lisocabtagene maraleucel in B-cell non-Hodgkin lymphoma, sponsored by Celgene Corporation. Started Oct 2018; status: completed.
02
Drugs
lisocabtagene maraleucel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03575351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575351.